ChromaDex and Ro Partner for New Product Development
May 04 2021 - 6:33AM
Business Wire
ChromaDex and healthcare technology company Ro announce supply
agreement for Niagen®
ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered
into a strategic supply agreement for Niagen® with Ro, a
healthcare-technology company. The agreement provides Ro with
rights to ChromaDex’s patented nicotinamide riboside ingredient
Niagen®, the sole active ingredient in Tru Niagen®, for specially
formulated Roman products.
“Ro has made great strides in a short period of time and we are
looking forward to working with them to improve the well-being of
their customers through healthy aging with Tru Niagen®,” said Frank
Fazio, Senior Vice President of Global Business Development at
ChromaDex.
“We look forward to working with the highly respected team at
ChromaDex who has pioneered breakthrough clinical evidence
surrounding Niagen®,” said George Koveos, Chief Operating Officer
at Ro.
As demonstrated in published human trials, Niagen® safely and
effectively increases NAD+ (nicotinamide adenine dinucleotide)
levels, which are critical to healthy cellular function and
vitality. Levels of NAD+ decline with age, which can be further
exacerbated by other metabolic and environmental stressors,
including stress on the immune system, sleep disruption, sun
exposure, and alcohol consumption.
For additional information about ChromaDex, please visit
www.chromadex.com.
For additional information about Ro, please visit www.ro.co.
About ChromaDex: ChromaDex Corp. is a global bioscience
company dedicated to healthy aging. The ChromaDex team, which
includes world-renowned scientists, is pioneering research on
nicotinamide adenine dinucleotide (NAD+), levels of which decline
with age. ChromaDex is the innovator behind NAD+ precursor
nicotinamide riboside (NR), which is protected by ChromaDex’s
patent portfolio along with other NAD+ precursors. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
About Ro: Ro is the healthcare technology company
building a patient-centric healthcare system. Ro’s vertically
integrated primary care platform powers a personalized, end-to-end
healthcare experience from diagnosis, to delivery of medication, to
ongoing care. With a nationwide provider network, in-home care API,
and proprietary pharmacy distribution centers, Ro seamlessly
connects telehealth, diagnostics, and pharmacy services to provide
high-quality, affordable healthcare without the need for insurance.
Since 2017, Ro has facilitated more than six million digital
healthcare visits in nearly every county in the United States,
including 98% of primary care deserts. Visit Ro.co for more
information.
Forward-Looking Statements: This release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities and Exchange Act of 1934, as amended, including
statements related to the results of clinical studies. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects," "anticipates,"
"intends," "estimates," "plans," "potential," "possible,"
"probable," "believes," "seeks," "may," "will," "should," "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2020, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504005399/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of Finance and Investor Relations
949-419-0288 ext. 127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024